PROGRAM DEVELOPMENT GRANT ON BREAST CANCER

乳腺癌是美国女性中最常见的癌症。 1993年估计有175 000个新病例。目前， 九分之一的美国女性在其一生中会患上乳腺癌。 乳腺癌的发病率每年增加2-3%， 在绝经前和绝经后妇女中。乳腺癌 是女性癌症死亡的第二大原因， 预计1993年将有45 000人死于乳腺癌。 整合 基础科学研究与临床研究的结合是关键， 解决乳腺癌病因学和治疗中的关键问题。 P20乳腺癌项目发展补助金的重点是分子 在乳腺癌病因学和治疗的目标，将涉及两个中心 在俄亥俄州州立大学。OSU综合癌症中心 （OSUCCC）和该中心的亚瑟G.詹姆斯癌症医院和研究 研究所（英联邦人权倡议）为多学科提供了重要机会 乳腺癌的实验室和临床研究相互作用。中心 俄亥俄州州立大学的分子环境健康（CMEH） 重点研究分子毒理学、分子流行病学， 分子病理学此外，核心的关键教师和研究人员在 OSUCCC，CMEH，以及相关的医学，药学， 兽医和生物科学致力于乳腺癌 研究和乳腺癌转化研究的发展。 该P20计划发展赠款的研究人员的核心 乳腺癌涉及几个OSUCCC基础科学（激素和 癌症、致癌作用、治疗学、基因表达）和临床 程序（外科肿瘤学，血液学/肿瘤学）。研究优势 内分泌学、发育治疗学、基因表达和 致癌作用允许整合这项研究的独特机会 纳入新的计划，重点是乳腺癌的转化研究目标 癌症病因学和治疗。 P20计划发展补助金的总体主题涉及分子 乳腺癌的病因和治疗。研究项目中心 围绕小分子（类固醇，天然产物， 合成试剂、环境试剂）和大分子（肽和 蛋白质激动剂/拮抗剂、抗体）与关键生物分子 乳腺癌的靶点（酶、受体、DNA）。研究项目和 该提案的发展计划有几个重要的内容 乳腺癌病因学领域的多学科重点， 疗法项目的转化研究目标集中在 将这些领域的基础科学整合和转移到临床 在P20提案的四年期间， 主要成分 该P20计划开发补助金的内容包括：（1）计划说明 领导，（2）对参与研究者的讨论，他们的研究 活动和发展计划，（3）发展计划 强调新的跨学科项目的环境因素， 乳腺癌和开发新的乳腺癌疗法，（4）预算， （五）证明文件。

Mammary adenocarcinoma is the most common cancer among women in the United States, with an estimated 175,000 new cases occurring in 1993. Currently, one out of nine American women will develop breast cancer in her lifetime. The rate of breast cancer incidence has increased 2-3% per year over the past decade in both premenopausal and postmenopausal women. Breast cancer is the second major cause of cancer deaths in women, and approximately 45,000 deaths from breast cancer are anticipated in 1993. The integration of basic science research with clinical investigations is critical in addressing key issues in breast cancer etiology and therapy. The P20 Program Development Grant on Breast Cancer focuses on molecular targets In breast cancer etiology and therapy and will involve two centers here at The Ohio State University. The OSU Comprehensive Cancer Center (OSUCCC) and the Center's Arthur G. James Cancer Hospital and Research Institute (CHRI) provide important opportunities for multidisciplinary laboratory and clinical research interactions in breast cancer. The Center for Molecular Environmental Health (CMEH) at The Ohio State University emphasizes research in molecular toxicology, molecular epidemiology, and molecular pathology. Furthermore, a core of key faculty and researchers in the OSUCCC, the CMEH, and associated Colleges of Medicine, Pharmacy, Veterinary Medicine, and Biological Sciences are committed to breast cancer research and the development of translational studies in breast cancer. The nucleus of investigators of this P20 Program Development Grant on Breast Cancer are involved in several OSUCCC Basic Sciences (Hormones and Cancer, Carcinogenesis, Therapeutics, Gene Expression) and Clinical Programs (Surgical Oncology, Hematology/Oncology). Research strengths in areas of endocrinology, developmental therapeutics, gene expression, and carcinogenesis permit unique opportunities for integration of this research into new programs focusing on translational research objectives in breast cancer etiology and therapy. The overall theme of the P20 Program Development Grant addresses molecular targets In breast cancer etiology and therapy. The research projects center around the interactions of small molecules (steroids, natural products, synthetic agents, environmental agents) and large molecules (peptide and protein agonists/antagonists, antibodies) with critical biomolecular targets in breast cancer (enzymes, receptors, DNA). Research projects and developmental programs of the proposal have several important multidisciplinary focuses in the areas of breast cancer etiology and therapy. Translational research objectives of the projects focus on integration and transfer of the basic sciences in these areas into clinical practice in the four year period of the P20 proposal. The major components of this P20 Program Development Grant are (1) description of the program leaders, (2) discussions on the investigators involved, their research activities, and developments of the program, (3) the development plan emphasizing new interdisciplinary projects in environmental factors in breast cancer and development of new breast cancer therapies, (4) budgets, and (5) supporting documents.